XOMA Royalty Corporation (NASDAQ:XOMA) Receives Consensus Recommendation of “Hold” from Analysts

Shares of XOMA Royalty Corporation (NASDAQ:XOMA) have been assigned a consensus rating of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $53.75.

A number of equities research analysts have recently issued reports on XOMA shares. Benchmark cut shares of XOMA Royalty from a “buy” rating to a “hold” rating in a report on Friday, May 22nd. Weiss Ratings raised shares of XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 29th. HC Wainwright cut shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 target price on the stock. in a report on Thursday, April 30th. Lucid Cap Mkts cut shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Finally, Zacks Research raised shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th.

XOMA Royalty Price Performance

Shares of XOMA stock opened at $42.15 on Monday. The company has a debt-to-equity ratio of 0.96, a quick ratio of 3.59 and a current ratio of 3.59. The firm’s 50-day moving average is $41.39 and its 200-day moving average is $32.57. The stock has a market cap of $528.56 million, a price-to-earnings ratio of 26.85 and a beta of 0.88. XOMA Royalty has a 52-week low of $22.29 and a 52-week high of $42.81.

XOMA Royalty (NASDAQ:XOMA) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). The firm had revenue of $12.32 million during the quarter, compared to the consensus estimate of $13.91 million. XOMA Royalty had a net margin of 53.46% and a return on equity of 12.56%. Sell-side analysts predict that XOMA Royalty will post 0.9 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of XOMA. Woodline Partners LP raised its holdings in XOMA Royalty by 7.9% in the 1st quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock valued at $3,359,000 after acquiring an additional 12,284 shares during the period. Geode Capital Management LLC raised its holdings in XOMA Royalty by 9.1% in the 2nd quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after acquiring an additional 16,929 shares during the period. JPMorgan Chase & Co. raised its holdings in XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 543 shares during the period. Rhumbline Advisers raised its holdings in XOMA Royalty by 18.0% in the 2nd quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock valued at $334,000 after acquiring an additional 2,019 shares during the period. Finally, Marshall Wace LLP raised its holdings in XOMA Royalty by 12.2% in the 2nd quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company’s stock valued at $411,000 after acquiring an additional 1,775 shares during the period. 95.92% of the stock is owned by institutional investors.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.